Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug : Adalimumab as starting anti-TNF-&#945; therapy in childhood chronic uveitis by G. Simonini et al.
Simonini et al. Pediatric Rheumatology 2013, 11:16
http://www.ped-rheum.com/content/11/1/16RESEARCH Open AccessSuperior efficacy of Adalimumab in treating
childhood refractory chronic uveitis when used as
first biologic modifier drug: Adalimumab as
starting anti-TNF-α therapy in childhood chronic
uveitis
Gabriele Simonini1*, Andrea Taddio2, Marco Cattalini3, Roberto Caputo4, Cinzia de Libero5, Fulvio Parentin5,
Ilaria Pagnini1, Loredana Lepore2 and Rolando Cimaz1Abstract
Background: Nonetheless biologic modifier therapies are available treatment strategies for sight-threatening uveitis
in children, the lack of evidence from head-to-head randomized controlled studies limits our understanding of
timing of therapy when to commence therapy, which agent to choose and how long to continue treatment, and,
in case of failure, if switching to another anti-TNF-α strategy might be eventually an option. Our aim was to
compare the efficacy of Adalimumab when used as first anti-TNFα therapy versus Adalimumab used after the failure
of a previous anti-TNFα (Infliximab) in an open-label, comparative, multi-center, cohort study of childhood chronic
uveitis.
Methods: 26 patients (14 F, 12 M; median age: 8.6 years) with refractory, non-infectious active uveitis were enrolled.
Due to the refractory course of uveitis to previous DMARD treatment, Group 1 received Adalimumab (24 mg/sq mt,
every 2 weeks), as first anti-TNFα choice; Group 2 received Adalimumab, as second anti-TNFα drug, due to the loss
of efficacy of Infliximab, administered after a period of at least 1 year. Both groups received Adalimumab for at least
1 year of treatment. Primary outcome was, once remission was achieved, the time to a first relapse.
Results: 14 children (10 with JIA, 3 with idiopathic uveitis, 1 with Behçet’s disease) were recruited in Group 1; 12
children (7 with JIA, 3 with idiopathic uveitis, 1 with early-onset sarcoidosis, 1 with Behçet’s disease) in Group 2.
Group 2 showed a lower probability to steroid discontinuation during the first 12 months of treatment (Mantel-Cox
χ24.12, p<0.04). In long-term follow-up, Group 1 had higher probability of uveitis remission during the time of
treatment on Adalimumab (median ±SE: 18 ±1.1 vs 4 ±0.6 months, CI 95%: 15.6-27.5 vs 2.7-5.2, Mantel-Cox χ210.12,
p<0.002).
Conclusions: Even if limited to a relatively small group, our study suggests a better efficacy of Adalimumab when
used as first anti-TNFα treatment in childhood chronic uveitis.
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Non-infectious, chronic uveitis in childhood is a relatively
uncommon, but serious disease, with the potential for sig-
nificant long-term complications and possible blindness
[1-3]. To date, nonetheless the fare cumulative data, there
is a compelling body of evidence that biologic modifier
therapies are available treatment strategies for sight-
threatening uveitis in children [4-16]. However, the lack of
evidence from head-to-head randomized controlled studies
limits our understanding of when to commence therapy,
which agent to choose and how long to continue treatment,
and, in case of failure, if switching to another anti-TNF-α
strategy might be eventually an option. Currently, only an
evidence level of III supports the treatment with immuno-
suppressive/biological modifiers drugs: expert opinion, clin-
ical experience or descriptive studies.
We recently showed, in a multicenter, comparative pro-
spective case series (evidence level IIb) the superior efficacy
of Adalimumab compared to Infliximab in maintaining
long-lasting remission in immunosuppressive-refractory
childhood chronic uveitis [17]. Moreover, we reported a
previous evidence of the loss of efficacy of Infliximab in
long-term follow-up [18].
Nonetheless, the clinical question of which anti-TNF-α
blocker seems more suitable for starting treatment in
childhood auto-immune uveitis is still unsolved and
debating.
In order to address this point, the purpose of this study
was to compare the efficacy of Adalimumab, when used as
first anti-TNF-α therapy, versus Adalimumab, used after
the failure of a previous anti-TNFα (Infliximab), in child-
hood non-infectious chronic uveitis.Methods
Study design
Prospective, comparative case series open-label study of
pediatric patients with refractory uveitis treated with
Adalimumab, for at least one year period at three ter-
tiary pediatric rheumatology centers in Italy: Anna
Meyer Children’s Hospital, Florence; Institute of Child
Health IRCCS Burlo Garofolo, Trieste and Paediatric
Clinic, University of Brescia.Inclusion criteria
To be considered eligible for this study, patients were re-
quired to have disease onset prior to 16 years, vision
threatening non-infectious uveitis that was refractory to
therapy with systemic corticosteroids and at least one other
immunosuppressive medication, or to be intolerant to such
therapy. ‘Refractory’ was considered as persistently active
uveitis for at least 3 months despite systemic cortico-
steroids and immunosuppressive treatment (Methotrexate
[MTX] and/or Cyclosporin A [CSA]).Study and treatment protocol
At the time of enrolment, medical history and complete
rheumatologic and ophthalmologic examinations were
performed in addition to a tuberculin purified protein
derivative skin test and a chest radiograph.
Due to the refractory course of uveitis to previous
DMARD treatment, after stopping the previous immuno-
suppressive therapy (except corticosteroids), eligible chil-
dren were consecutively enrolled in 2 groups, receiving
Adalimumab at the dose of 24 mg/sq.mt, subcutaneously
every 2 weeks, for at least 1 year:
 Group 1 received Adalimumab, as first anti-TNF-α
choice, naïve from any anti-TNFα treatment;
 Group 2 received Adalimumab, as second anti-TNF-α
drug, after a previous treatment course with Infliximab.
In this group, when Infliximab, administered for at
least 1 year at 5–10 mg/kg weeks at 0, 2, 6 and then
every 6–8 weeks, lost efficacy due to persistent/
refractory uveitis, children were then switched to
Adalimumab. Of note, during Infliximab treatment,
children had been receiving MTX treatment at very
low dosages (5–7.5 mg/week) in order to prevent the
formation of anti-infliximab autoantibodies.
At enrolment, steroid therapy was maintained at stable
dose (prednisone 1–2 mg/kg/day) for at least 6 weeks,
and then tapered once remission was achieved with re-
gard to uveitis activity.
The choice of timing of Adalimumab as TNF-α inhibi-
tor was an opinion-based decision of the treating oph-
thalmologist and rheumatologist in collaboration and on
the basis on drug availability at their own center at the
date of starting the anti- TNF-α therapy.
Every 30–45 days, children received a routine assess-
ment, including a general physical examination, laboratory
evaluation with renal and liver function tests, complete
blood count and inflammation parameters and a complete
ophthalmologic evaluation, including best corrected visual
acuity (BCVA) on Snellen eye charts and slit lamp exam-
ination, that was performed at study enrolment and
according to the degree of activity thereafter. Once uveitis
achieved remission, children underwent an ophthalmo-
logic evaluation at each assessment or otherwise on clin-
ical demand as needed. In both groups, therapy was
withdrawn if major side effects/complications due to the
treatment increased and/or lack of efficacy appeared.
The exact same protocol was applied in the three cen-
ters. Each local ethic committee gave their approval. Par-
ents or guardians gave their informed consent.
Patients
All of the patients in this series were recruited from the
Pediatric Rheumatology Units in Florence, Brescia, and
Trieste from June 2007 to November 2010.
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following a total of 188 pediatric patients with chronic
uveitis (127 females, 61 males, median age 6 years, range
3–18 years); 119 were associated with juvenile idiopathic
arthritis (JIA), 10 with Behçet’s disease, 1 with early-onset
sarcoidosis, and 9 with other connective tissue diseases
(systemic lupus erythematosus or mixed connective tissue
disease), while the other 49 had idiopathic uveitis.
Twenty-six children (14 females, 12 males, median age
8.6, range 5.2-13.8 years) resulted in being eligible for the
study and were enrolled: 17 were recruited in Florence, 6
in Trieste, 3 in Brescia. In 20 of 26 children, uveitis was
associated with an underlying autoimmune disease: 17 JIA
(9 oligoarticular, 5 extended oligoarticular, 3 RF-negative
polyarticular), 1 early-onset sarcoidosis, 2 Behçet’s disease.
The other 6 children had idiopathic uveitis. Among 9/20
patients with secondary uveitis, at enrolment, the associ-
ated underlying disease was active despite concomitant
medications, while the remaining 11 patients were in re-
mission on therapy with regard the associated disease, but
not to uveitis. Before Adalimumab treatment, all children
had presented active uveitis: 33/52 involved eyes, despite
treatment with MTX at the dosage of 15 mg/m2/weekly
(n = 17), CSA at the dosage of 3 mg/kg/day (n = 6) and the
combined administration of MTX and CSA (n = 3). Due
to active uveitis, along with topical steroids during the
acute phase, all of the children were also receiving oral
prednisone (1–2 mg/kg/day), at stable dose for at least
6 weeks (range 43–56 days).
Main outcome measures
In order to assess long-lasting effect on maintaining remis-
sion, the primary outcome was to assess, once remission
was achieved, the time of a first relapse during treatment.
In addition, secondary outcomes were to compare, once
anti-TNF-α treatment was started, time to uveitis remis-
sion, time to steroid discontinuation, and the number of
uveitis relapses. According to the Standardization of
Uveitis Nomenclature Working Group grading schemes,
uveitis activity, as grade ≥ 1+, was defined improved when
decreased by 2 steps in the level of inflammation or de-
creased to grade 0 [19]. As previously reported, “improved”
visual acuity, converted into a logMAR format, was defined
as a doubling, “worsened” as a halving of the visual angle
in at least 1 eye [20].
Statistical analysis
Mann–Whitney U test, Wilcoxon’s signed rank test for
paired samples, chi-square tests, McNemar test, and Fish-
er’s exact test, when appropriate, were used to compare
data. Two-tailed P values were employed. An a priori power
analysis was completed using G Power program [21]. Con-
sidering current data of refractory uveitis in children, a
large expected difference was estimated for the sample: theeffect size F = 0.40, as per Cohen [22]. In addition, power
was set at 0.95, meaning there would be a 95% probability
of reaching statistical significance if the obtained differences
were truly present in the population. Results from the
power analysis showed that 28 participants, 14 for each
arm, in all groups combined would be required. The follow-
ing data, entered into a customized uveitis database, were
considered as variables for correlations and as covariates
for the survivage at the initiation of/age at the initiation of
anti-TNFα therapy, gender, associated autoimmune disease,
disease duration, age at uveitis onset, uveitis duration, active
uveitis duration, time interval between the uveitis onset and
the initiation of anti-TNFα therapy, concomitant medica-
tions, previous cumulative corticosteroid dose and its dur-
ation, previous disease modifying anti-rheumatic drug
treatment duration, number of previous flares, number of
patients with eye complications due to chronic uveitis (in-
cluding glaucoma, synechiae, band keratopathy, cystoid
macular edema, vitreitis, and cataract), and follow-up time.
Pearson’s and Spearman’s correlation tests were used to de-
termine correlation coefficients for different variables. In
order to identify predictors of outcome, Cox regression
model and Kaplan-Meier curves were constructed, each
one at the mean of the covariates reported above. All ana-
lyses were performed with the SPSS package for Windows,
version 13.0.
Results
Fourteen children (9 females, 5 males), 10 affected by JIA,
3 by idiopathic uveitis, and 1 by Behçet’s disease, were
recruited in Group 1, thus receiving Adalimumab as first
anti-TNF-α drug. Twelve children (7 females, 5 males), of
whom 7 were affected by JIA, 3 by idiopathic uveitis, 1 by
early-onset sarcoidosis, and 1 by Behçet’s disease, were en-
rolled in Group 2, who received Adalimumab as second
anti-TNF-α drug.
The total median length of uveitis duration before
Adalimumab treatment was significantly higher in Group 2
than in Group 1: 28 months, range 22–34, vs 16 months,
range 12–22 (p = 0.001). Demographic information and
other reported variables in the statistical analysis section,
acting as covariates, did not differ in the two groups. Dur-
ing the time of treatment, Adalimumab was not able to
control eye inflammation during the first year of treatment
in one JIA child, belonging to Group 1; therefore, she never
achieved remission and was considered “non-responder”.
She therefore resulted in being eligible for the inclusion cri-
teria (refractory uveitis), but not for our primary outcome
measure (absence or recurrence of uveitis), and therefore
was excluded from the long-term survival analysis.
Cox-regression analysis, at mean of the above mentioned
covariates, including the total length of follow-up time, did
not show statistical significant differences between the two
groups with regard to time to achieve remission, even
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sion was observed for Group 2: median period (range)
16 weeks (range 12–18) vs 12 weeks (range 8–16).
Seventeen children (12 in Group 1 and 5 in Group 2)
were able to stop steroid administration during the first
6 months from the start of Adalimumab, and all re-
sponders discontinued steroid before 1 year of treat-
ment. However, Cox-regression showed that patients in
Group 2 needed a longer time to discontinuation of ste-
roids (median ± SE: 7 ±1.7 vs 3 ±0.9 months, CI 95%:
3.6-10.4 vs 1.1-4.8, p < 0.001) and a lower probability to
steroid discontinuation during the first 12 months of
treatment (log-rank, Mantel-Cox χ2 4.12, p < 0.004)
(Figure 1a).
With regard to our primary outcome measure, at the
mean of the above mentioned covariates, including the
total length of follow-up time of the 2 groups, Cox re-
gression analysis showed that, during the time of treat-
ment on Adalimumab, Group 1, compared to Group 2,
had higher probability of uveitis remission, considered as
time to first flare, (log-rank, Mantel-Cox χ2 10.12,
p < 0.002) and longer time on remission on treatment:
median ± SE: 18 ±1.1 vs 4 ±0.6 months, CI 95% 15.6-
27.5 vs 2.7-5.2, p < 0.001) (Figure 1b).
During the first year of treatment, no relapse of uveitis
occurred in all 13 responders on Group 1, whilst, among
12 children in group 2, just 2 children with JIA were still
on remission, while the remaining 10 children experi-
enced a median number of relapses of 2 (range 1–5).
After the 1-year follow-up visit, among responders,
11 (84.5%) of 13 children in Group 1 and 2 (16.5%) of
12 children in Group 2 met the criteria for improvedGroup 1, n=14 ; Group 2, n=12 
(a)
Figure 1 Time to steroid discontinuation and time on remission up to
steroid discontinuation (months) for the Group 1 (black curve), receiving A
receiving Adalimumab as second anti-TNFα therapy. On the y-axis, the pro
Mantel-Cox χ2 4.12, p < 0.004). b. Survival curves up to the first uveitis relap
curve), receiving Adalimumab as first anti-TNFα therapy, and Group 2 (grey
y-axis, the probability of patient being on remission on anti-TNF-α therapyvisual acuity (χ2: 11.5, p < 0.001), corresponding to 16
(61.5%) of 26 eyes and 3 (12.5%) of 24 eyes, respectively
(χ2: 12.7, p < 0.001) (Figure 2a-b).
At the 1-year follow-up, the number of patients as well
as the number of eyes within a “normal visual acuity”
was significantly higher than before treatment for Group
1 (11/13 patients vs 4/13 patients, p <0.008; and 19/26
eyes vs 7/26 eyes, p <0.001), whilst we did not observe
significant differences with regard to Group 2 (5/12 pa-
tients vs 4/12 patients; and 9/24 eyes vs 8/24 eyes).
At 1 year of treatment, we detected significant differ-
ences between the two groups with regard to the num-
ber of children and number of eyes within a “normal
visual acuity” (χ2: 4.9, p < 0.04; and χ2: 6.4, p < 0.02, re-
spectively) (Figure 2c-d).
In addition, we performed a sub-group analysis limited
just to children with JIA: 9 belonging to the Group 1, and
7 to the Group 2. With regard to our primary and second-
ary outcomes, we obtained similar statistical results. Cox
regression analysis showed that Group 1 had a higher
probability of uveitis remission compared to Group 2 (log-
rank, Mantel-Cox χ2 12.83, p < 0.002), and longer time on
remission on treatment: median ± SE: 19 ±0.9 vs 6 ±1.2 -
months, CI 95% 16.5-28.6 vs 3.6-6.4, p < 0.001). We did
not observe any statistical differences between the two
groups with regard to the time to uveitis remission. In-
stead, children in Group 1 have been able to discontinue
systemic steroid administration before than children in
Group 2 (median ± SE: 2 ±0.3 vs 6 ±0.7 months, CI 95%:
1.1-3.8 vs 3.6-8.4, p < 0.001), and had higher probability to
stop steroid during the first 12 months (log-rank, Mantel-
Cox χ2 5.21, p < 0.003).Group 1, n=13 ; Group 2, n=12 
(b)
the first relapse on Adalimumab. a. Survival curves of time to
dalimumab, as first anti-TNFα therapy, and the Group 2 (grey curve),
bability of patient being on steroid treatment is shown. (log-rank,
se on therapy after achieving remission (months) for Group 1 (black
curve), receiving Adalimumab as second anti-TNFα therapy. On the
is shown (log-rank, Mantel-Cox χ2 10.12, p < 0.002).
(a) (b)
(c) (d)
Figure 2 Improved and normal visual acuity on Adalimumab. a-b. Number of children (a) as well the number of eyes (b) with improved (black
bar) and not improved (white bar) visual acuity at 1 year of treatment in Group 1, receiving Adalimumab as first anti-TNFα therapy, and Group 2,
receiving Adalimumab as second anti-TNFα therapy. (χ2: 11.5, p < 0.001; and χ2: 12.7, p < 0.001, respectively). c-d. Number of children (c) as well
number of eyes (d) with normal (black bar) and abnormal (white bar) visual acuity at 1 year of treatment in Group 1, receiving Adalimumab as first
anti-TNFα therapy, and in Group 2, receiving Adalimumab as second anti-TNFα therapy (χ2: 4.9, p < 0.04; and χ2: 6.4, p < 0.02, respectively).
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Group 1 and 2 (28.5%) of 7 children in Group 2 met the
criteria for improved visual acuity (χ2: 6.11, p < 0.03),
corresponding to 11 (61.1%) of 18 eyes and 3 (21.4%) of
14 eyes, respectively (χ2: 5.03, p < 0.03).
None of the patients were amblyopic and refractive er-
rors were corrected by means of glasses or contact lenses.
All recorded variations in best-corrected visual acuity
were therefore related to disease activity and no clearance
of media was recorded.
Discussion
Even if limited to a relatively small group, this comparative
cohort-study suggests a better efficacy of Adalimumab
when used as first anti-TNF-α treatment in chronic child-
hood uveitis, with regard to time of first flare, once remis-
sion has been achieved.
To our knowledge, RCTs on this topic have not yet been
published to date, and our study represents the first pro-
spective cohort comparative study assessing differences in
timing use of anti-TNF-α treatment for childhood chronic
refractory uveitis. Based on these data, if our results will be
duplicated in a larger and homogenous cohort, the evidenceof this different timing in using anti-TNF-α therapy will
reach a level of evidence of IIb, better than the actual know-
ledge (level of evidence of III).
Recently published case series suggested that in case
of refractory uveitis with lack of initial clinical response
to one anti-TNF-α agent, switching to another one could
achieve control of intraocular inflammation [23]. Ac-
cordingly, Biester et al. also reported favorable results
with Adalimumab when Infliximab or Etanercept were
not effective or not tolerated, but also good effects with
Etanercept or Infliximab in case of lack of response to
Adalimumab [24]. Conversely, our study does not seem
to confirm these findings. However, the former studies
reported their mono-center experience by a retrospect-
ive analysis on smaller, not comparative, case series; we
addressed this topic by a prospective comparative ana-
lysis of 26 children from different Italian centers. The
different approach could explain at least in part these
differences.
Of note, before drawing firm conclusions from our re-
sults, some caveats have to be discussed and considered. Of
course, the small sample size due to the rarity of the disease
limits our study results. The heterogeneity of the sample
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the inherent selection bias of 3 tertiary referral centers,
might also affect the results of our study, overweighting the
obtained data. However, our study population resulted
homogenous for the primary outcome study (childhood
refractory chronic uveitis), and, due to the small number
of potential eligible subjects, a more conservative inclu-
sion criteria of population would hamper the a-priori
power analysis, thus stronger affecting the results. The
longer follow-up period, thus the longer disease duration,
in the Group 2 could have been inferring the data, resulting
in a non-homogenous comparison. In addition, children in
Group 2, receiving much longer treatment, not controlling
the disease, might have been also acquired an irreversible
damage, losing the chance to improve, regardless the
administered treatment. Hence failure to respond to
Adalimumab would not be surprising. We thought
to minimize this effect bias considering the length of
follow-up as a covariate for the survival curves, therefore
overweighting its potential effect size.
Conversely what we previously reported [17], the present
study seems to show that Adalimumab looses the capacity
to maintain longer remission period if used as second anti-
TNFα treatment in childhood chronic uveitis, refractory to
a previous anti-TNF treatment (Infliximab). We are not
able to explain this biological phenomenon and it is also
likely that this is not specific for Adalimumab neither for
childhood uveitis, since other anti-TNF agents in different
diseases (i.e. Rheumatoid Arthritis) can do the same. Even
though our study design is not able to address this point,
we can hypothesize that, during the biological modifiers ad-
ministration, the immune system, with their ongoing use,
learns to drive on alternative pathways, bypassing the TNFα
blockade. In this clinical setting, switching to another class
of biological modifiers drugs, such as Abatacept, seems a
reasonable strategy rather than maintaining an anti TNF-α
option. Indeed, in our clinical practice of childhood chronic
uveitis, when a first anti-TNF-α treatment fails, we switch
to the co-stimulatory blocker [25,26].
Conclusions
Clinical practice guidelines and consensus statements on
the criteria of introduction, duration of treatment and ces-
sation of TNF antagonists, including safety issues, are
strongly advocated and a constant revision as data
from longer periods of patient exposure accumulate is
warranted. Facing children with autoimmune chronic uve-
itis, refractory to steroids as well as to conventional im-
munosuppressant therapy, prone to a clinical dilemma:
which anti-TNF-α strategy should we prescribe for that
child? Even if not coming from an evidence level of I or II,
it is a diffuse experience that Etanercept is not suggested
as a first choice treatment in refractory childhood auto-
immune chronic uveitis [3,27]. The present comparativeprospective study, along with the former one [17], might
suggest clinicians to consider Adalimumab as potential
starting option in case of childhood chronic refractory
uveitis.
Further studies in a larger cohort, in a prospective
fashion, preferably by a randomized clinical trial, focused
on one disease entity with a sufficient sample size, seem
to be advocated to address this point.
Key messages
Adalimumab, when used as first anti-TNF-α treatment
in chronic, refractory childhood uveitis, shows a better
efficacy than used as second line anti-TNF-α agent.
In clinical practice, Adalimumab might be the first
starting option in case of refractory childhood uveitis.
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